ENDOTHELIAL FUNCTION PREDICTS ANTHRACYCLINE-INDUCED CARDIOTOXICITY

Evangelos Oikonomou(National and Kapodistrian University of Athens), George-Angelo Papamikroulis(National and Kapodistrian University of Athens), Pavlos Papakostas(Hippocration General Hospital), Gerasimos Siasos(Brigham and Women's Hospital), Μaria Anastasiou(National and Kapodistrian University of Athens), Alexios S. Antonopoulos(National and Kapodistrian University of Athens), Flora Zagouri(National and Kapodistrian University of Athens), Θεοδώρα Ψαλτοπούλου(Alexandra Hospital), Sotirios Tsalamandris(Hippocration General Hospital), Aristotelis Bamias(National and Kapodistrian University of Athens)
Journal of the American College of Cardiology
March 1, 2018
10.1016/s0735-1097(18)32627-5
Cited by 2

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data
|The Lancet|2018|1.1k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography
|European Heart Journal|2019|503